In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

British Biotech merges with RiboTargets

Executive Summary

Following talks that began in January, British Biotech (matrix metalloproteinase inhibitors, MMPIs) has agreed to merge with RiboTargets (anti-infectives and oncology drugs). RiboTargets' CEO Simon Sturge becomes CEO of the new biotech company, which will be 50.01% owned by the shareholders of BB, and 49.99% by RiboTargets.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Partial Acquisition
    • Payment Includes Stock

Related Companies